Cure TV

Raghav Sundar, M.B.B.S., M.R.C.P., M.Med., National University Health System in Singapore, discusses the possibility of cooling limbs during chemotherapy infusions to prevent chemotherapy-induced peripheral neuropathy. In a clinical trail of patients with breast cancer, this device showed proof of concept.

For years, Eric Gelber has been embarking on long distance runs to raise money for the Multiple Myeloma Research Foundation. This September, he will attempt his longest run yet: 200 miles through Central Park over the course of a weekend

Supriya Mohile, director of the Geriatric Oncology clinic at the University of Rochester Wilmot Cancer Institute, explains that when geriatric patients visit their doctors and oncologists, it is important to express their worries and any side effects that they are experiencing.

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.

Ricardo J. Bello, postdoctoral research fellow at Johns Hopkins School of Medicine, discusses the importance of patient education to drive the decision-making process in breast reconstruction and surgery. With more knowledge, they can ask higher level questions and help the field thrive.

Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.

Barbara Van Husen, president of the MPN Research Foundation, discusses how after the discovery of the JAK2 mutation in 2005, MPN research and treatment advances proliferated. Now, Van Husen says, it is one of the most active areas of hematological research